Aldeyra The(ALDX)

Biotechnology · Lexington, MA

$0.92-0.25 (-21.05%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T10:50:36.118Z.

Stored calculation inputs

Calculation as of: 2026-10-06T10:50:36.118Z.

Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -23,800,336
Quote market capitalization: 55,718,571
Total debt · period ending 2026-06-30: 143,447
Cash · period ending 2026-06-30: 45,089,786

FMP input reference: 465112d98a6c82939a581bc37d9e1b887570666ec45509b145499b9afd19c223

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ALDX EBITDA Yield Metrics

EBITDA YIELD

N/A

ALDX Competitors' EBITDA Yield

ALDX

Aldeyra The

Current

Market Cap

$55.72M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CNTB

Connect Biopharma Holdings Limited

vs ALDX

Market Cap

$56.54M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BOLD

Boundless Bio, Inc.

vs ALDX

Market Cap

$58.43M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACET

Adicet Bio, Inc.

vs ALDX

Market Cap

$60.48M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

APLM

Apollomics, Inc.

vs ALDX

Market Cap

$50.51M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COCH

Envoy Medical, Inc.

vs ALDX

Market Cap

$50.25M

EBITDA Yield

N/A

TTM Avg

0.59%

3Y Avg

0.59%

5Y Avg

0.59%

CLNN

Clene Inc.

vs ALDX

Market Cap

$49.96M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CELU

Celularity Inc.

vs ALDX

Market Cap

$49.50M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BTMD

biote Corp.

vs ALDX

Market Cap

$49.40M

EBITDA Yield

11.15%

TTM Avg

20.03%

3Y Avg

16.76%

5Y Avg

21.84%

CING

Cingulate Inc.

vs ALDX

Market Cap

$63.98M

EBITDA Yield

465.14%

TTM Avg

3466.62%

3Y Avg

3466.62%

5Y Avg

3466.62%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Aldeyra The (ALDX)	$55.72M	N/A	N/A	N/A	N/A
Connect Biopharma Holdings Limited (CNTB)vs ›	$56.54M	N/A	N/A	N/A	N/A
Boundless Bio, Inc. (BOLD)vs ›	$58.43M	N/A	N/A	N/A	N/A
Adicet Bio, Inc. (ACET)vs ›	$60.48M	N/A	N/A	N/A	N/A
Apollomics, Inc. (APLM)vs ›	$50.51M	N/A	N/A	N/A	N/A
Envoy Medical, Inc. (COCH)vs ›	$50.25M	N/A	0.59%	0.59%	0.59%
Clene Inc. (CLNN)vs ›	$49.96M	N/A	N/A	N/A	N/A
Celularity Inc. (CELU)vs ›	$49.50M	N/A	N/A	N/A	N/A
biote Corp. (BTMD)vs ›	$49.40M	11.15%	20.03%	16.76%	21.84%
Cingulate Inc. (CING)vs ›	$63.98M	465.14%	3466.62%	3466.62%	3466.62%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

About Aldeyra The

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Lexington, MA

6 employees

www.aldeyra.com

Healthcare / Biotechnology